top of page
Harnessing the Natural Tropism of Mesenchymal Stem Cells to Cancer in A Drug Targeting Platform
NanoGhost is a biotech company that develops a highly selective first-in-class drug targeting platform (Nano-Ghosts/NGs) from the cell membrane of mesenchymal stem cells (MSCs), cells with known tropism to cancer and sites of inflammation.
NGs are nanovesicles equipped with inherent MSC targeting capabilities, ability to infiltrate inter and intra cellular niches, with versatile loading capacity and broad therapeutic applicability.
This technology is based on discoveries from the lab of Prof. Marcelle Machluf, Technion Institute of Technology, Israel.
Technology Overview
The Israel's Ministry of Science and Technology acknowledged
NanoGhost platform as one of Israel's 60 most impactful
developments and discoveries
bottom of page